How to apply results from randomized trials and systematic reviews to individual patient care: Clinical Research for Nephrologists

Nephrology

Volumn 15, Issue 3, 2010, Pages 277-280

  Hodson, Elisabeth M ^a,b   Craig, Jonathan C ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Data application; Individual patient care

Indexed keywords

ACICLOVIR; GANCICLOVIR; PLACEBO; VALACICLOVIR; VALGANCICLOVIR;

CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HUMAN; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; NEUROLOGIC DISEASE; PATIENT ASSESSMENT; PATIENT CARE; PATIENT CARE PLANNING; PATIENT IDENTIFICATION; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SHORT SURVEY; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EVIDENCE-BASED MEDICINE; HUMANS; INDIVIDUALIZED MEDICINE; PATIENT CARE; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVIEW LITERATURE AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 77950484754     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2010.01281.x     Document Type: Short Survey

References (8)

1. Hodson EM, Jones CA, Webster AC et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: A systematic review of randomised controlled trials. Lancet 2005 365 : 2105 2115.
2. Hodson EM, Craig JC, Strippoli GFM, Webster AC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst. Rev. 2008, Issue 2. Art. No.: CD003774. DOI: 10.1002/14651858.CD003774.pub3.
3. National Health and Medical Research Council. NHMRC Additional Levels of Evidence and Grades for Recommendations for Developers of Guidelines. Stage 2 Consultation: Early 2008 to End June 2009.
4. Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant. 2004 4 : 611 620. (Pubitemid 38523584)
5. National Health and Medical Research Council. How to Use the Evidence: Assessment and Application of Scientific evidence.
6. Glasziou PP, Irwig LM. An evidence based approach to individualising treatment. Br. Med. J. 1995 311 : 1356 1359.
7. Waiser J, Budde M, Schreiber M et al. Effectiveness of deferred therapy with ganciclovir in renal allograft recipients with cytomegalovirus disease. Transplant. Proc. 1998 30 : 2083 2085. (Pubitemid 28399435)
8. Smith SR, Butterly DW, Conlon PJ, Harland RC, Emovon OE. Incidence of cytomegalovirus in renal disease without antilymphocyte induction: Is prophylaxis necessary? Transplant. Proc. 1998 30 : 2097 2099.